224 related articles for article (PubMed ID: 3002245)
1. Drug resistance patterns of herpes simplex virus isolates from patients treated with acyclovir.
McLaren C; Chen MS; Ghazzouli I; Saral R; Burns WH
Antimicrob Agents Chemother; 1985 Dec; 28(6):740-4. PubMed ID: 3002245
[TBL] [Abstract][Full Text] [Related]
2. A mammalian cell line designed to test the mutagenic activity of anti-herpes nucleosides.
Pizer LI; Mitchell DH; Bentele B; Betz JL
Int J Cancer; 1987 Jul; 40(1):114-21. PubMed ID: 3036717
[TBL] [Abstract][Full Text] [Related]
3. Clinical isolate of herpes simplex virus type 2 that induces a thymidine kinase with altered substrate specificity.
Ellis MN; Keller PM; Fyfe JA; Martin JL; Rooney JF; Straus SE; Lehrman SN; Barry DW
Antimicrob Agents Chemother; 1987 Jul; 31(7):1117-25. PubMed ID: 2821890
[TBL] [Abstract][Full Text] [Related]
4. Low levels of herpes simplex virus thymidine- thymidylate kinase are not limiting for sensitivity to certain antiviral drugs or for latency in a mouse model.
Coen DM; Irmiere AF; Jacobson JG; Kerns KM
Virology; 1989 Feb; 168(2):221-31. PubMed ID: 2536980
[TBL] [Abstract][Full Text] [Related]
5. Isolation of bromovinyldeoxyuridine-resistant strains of herpes simplex virus and successful chemotherapy of mice infected with one such strain by using acyclovir.
Field HJ; Neden J
Antiviral Res; 1982 Oct; 2(5):243-54. PubMed ID: 6295272
[TBL] [Abstract][Full Text] [Related]
6. Occurrence and characterization of acyclovir-resistant herpes simplex virus isolates: report on a two-year sensitivity screening survey.
Nugier F; Colin JN; Aymard M; Langlois M
J Med Virol; 1992 Jan; 36(1):1-12. PubMed ID: 1315366
[TBL] [Abstract][Full Text] [Related]
7. Activities of 1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl)-5-iodocytosine and its metabolites against herpes simplex virus types 1 and 2 in cell culture and in mice infected intracerebrally with herpes simplex virus type 2.
Schinazi RF; Fox JJ; Watanabe KA; Nahmias AJ
Antimicrob Agents Chemother; 1986 Jan; 29(1):77-84. PubMed ID: 3015003
[TBL] [Abstract][Full Text] [Related]
8. Characterisation of acyclovir-resistant and -sensitive clinical herpes simplex virus isolates from an immunocompromised patient.
Christophers J; Sutton RN
J Antimicrob Chemother; 1987 Sep; 20(3):389-98. PubMed ID: 2824424
[TBL] [Abstract][Full Text] [Related]
9. Herpes simplex virus resistance to antiviral drugs.
Morfin F; Thouvenot D
J Clin Virol; 2003 Jan; 26(1):29-37. PubMed ID: 12589832
[TBL] [Abstract][Full Text] [Related]
10. Differential mechanism of cytostatic effect of (E)-5-(2-bromovinyl)-2'-deoxyuridine, 9-(1,3-dihydroxy-2-propoxymethyl)guanine, and other antiherpetic drugs on tumor cells transfected by the thymidine kinase gene of herpes simplex virus type 1 or type 2.
Balzarini J; Bohman C; De Clercq E
J Biol Chem; 1993 Mar; 268(9):6332-7. PubMed ID: 8384209
[TBL] [Abstract][Full Text] [Related]
11. Sensitivity monitoring of clinical isolates of herpes simplex virus to acyclovir.
Collins P; Ellis MN
J Med Virol; 1993; Suppl 1():58-66. PubMed ID: 8245894
[TBL] [Abstract][Full Text] [Related]
12. Genital herpes due to acyclovir-sensitive herpes simplex virus caused secondary and recurrent herpetic whitlows due to thymidine kinase-deficient/temperature-sensitive virus.
Shimada Y; Suzuki M; Shirasaki F; Saito E; Sogo K; Hasegawa M; Takehara K; Phromjai J; Chuhjo T; Shiraki K
J Med Virol; 2007 Nov; 79(11):1731-40. PubMed ID: 17854045
[TBL] [Abstract][Full Text] [Related]
13. In vitro selection of drug-resistant varicella-zoster virus (VZV) mutants (OKA strain): differences between acyclovir and penciclovir?
Andrei G; De Clercq E; Snoeck R
Antiviral Res; 2004 Mar; 61(3):181-7. PubMed ID: 15168799
[TBL] [Abstract][Full Text] [Related]
14. Highly reliable heterologous system for evaluating resistance of clinical herpes simplex virus isolates to nucleoside analogues.
Bestman-Smith J; Schmit I; Papadopoulou B; Boivin G
J Virol; 2001 Apr; 75(7):3105-10. PubMed ID: 11238837
[TBL] [Abstract][Full Text] [Related]
15. An acyclovir-resistant strain of herpes simplex virus type 2 which is highly virulent for mice.
Sakuma S; Yamamoto M; Kumano Y; Mori R
Arch Virol; 1988; 101(3-4):169-82. PubMed ID: 2845890
[TBL] [Abstract][Full Text] [Related]
16. Characterization of latent infections in mice inoculated with herpes simplex virus which is clinically resistant to acyclovir.
Field HJ; Lay E
Antiviral Res; 1984 Apr; 4(1-2):43-52. PubMed ID: 6331304
[TBL] [Abstract][Full Text] [Related]
17. Single nucleotide polymorphisms of thymidine kinase and DNA polymerase genes in clinical herpes simplex virus type 1 isolates associated with different resistance phenotypes.
Schubert A; Gentner E; Bohn K; Schwarz M; Mertens T; Sauerbrei A
Antiviral Res; 2014 Jul; 107():16-22. PubMed ID: 24747042
[TBL] [Abstract][Full Text] [Related]
18. Disease and latency characteristics of clinical herpes virus isolated after acyclovir therapy.
Sibrack CD; McLaren C; Barry DW
Am J Med; 1982 Jul; 73(1A):372-5. PubMed ID: 6285725
[TBL] [Abstract][Full Text] [Related]
19. Susceptibility to acyclovir of herpes simplex virus isolates obtained between 1977 and 1996 in Japan.
Hasegawa T; Kawana T; Okuda T; Horii M; Tsukada T; Shiraki K
J Med Virol; 2001 Jan; 63(1):57-63. PubMed ID: 11130888
[TBL] [Abstract][Full Text] [Related]
20. Comparative anti-herpesvirus activities of 9-(1,3-dihydroxy-2-propoxymethyl)guanine, acyclovir, and two 2'-fluoropyrimidine nucleosides.
Smee DF; Campbell NL; Matthews TR
Antiviral Res; 1985 Oct; 5(5):259-67. PubMed ID: 2998275
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]